|Takafumi Kimura M.D.,Ph.D.
[ Contact ]
The advent of induced pluripotent stem cells represents a significant contribution to the study of the fundamental mechanisms of early embryonic development, as well as great promise for future applications in the understanding of intractable diseases of the nervous, endocrine/metabolic and other systems, drug discovery and development and in cell-based regenerative therapies. The Facility for iPS cell Therapy (FiT) was established as a new core facility to support clinical research through techniques for the generation, expansion and induced differentiation of iPS cells. As a cell-processing center dedicated to the handling of iPS cells, FiT has been constructed to be able to produce batches of iPS cells in compliance with Good Manufacturing Practice (GMP) standards. We seek to introduce and test GMP-compliant cell culture methods in a timely manner so as to meet patients' expectations of future clinical uses of iPS cells. Achieving this goal will of course require the involvement of many other laboratories as well, and we are developing the necessary social systems to enable us to contribute to these efforts as a core laboratory.